drugset / Trial / NCT07213973

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973

Phase 2 Recruiting 40 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Timeline

Start
2026-02-02
Primary completion
2028-03-25
Completion
2028-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule Oral